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Abstract
Background and Objective The antipsoriatic effect of an
innovative aerosol foam formulation of fixed combination
calcipotriol 50 lg/g (as hydrate; Cal) and betamethasone
0.5 mg/g (as dipropionate; BD) was explored in order to
compare the effect with that of the first-line treatment Cal/
BD ointment.
Methods This was a Phase IIa, single-centre, investigator-
blinded, exploratory study, with intra-individual compar-
ison using a modified psoriasis plaque test. Patients were
treated once daily (6 days/week) for 4 weeks with Cal/BD
foam, Cal/BD ointment, BD foam and Cal/BD foam ve-
hicle, randomized to four plaque test sites (5 cm2 each).
The primary efficacy endpoint was change in total clinical
score (TCS; sum of erythema, scaling and lesional thick-
ness). Secondary endpoints included ultrasonographic
changes in total skin thickness and echo-poor band thick-
ness, and adverse events.
Results Twenty-four patients, median age 52.5 years
(range 21–75), completed this study. At week 4, test sites
treated with Cal/BD foam had a significantly greater
decrease in mean (±SD) TCS (-6.00 ± 1.27) versus those
treated with Cal/BD ointment (-5.25 ± 1.78; difference
-0.75; 95 % CI -1.46 to -0.04; p = 0.038), BD foam
(-4.96 ± 1.85; difference -1.04; 95 % CI -1.75 to
-0.33; p = 0.005) or foam vehicle (-1.88 ± 1.12; dif-
ference -4.13; 95 % CI -4.83 to -3.42; p \ 0.001). Total
skin thickness and echo-poor band thickness of Cal/BD
foam-treated sites were reduced to a greater extent than
those treated with comparators. Eleven patients reported 17
adverse events, the most frequent being headache (five
patients). There were no lesional/perilesional adverse
events or adverse drug-related events.
Conclusions Cal/BD foam demonstrated a significant
improvement in antipsoriatic effect over Cal/BD ointment,
BD foam and foam vehicle alone.
Key Points
An innovative aerosol foam formulation of a fixed
combination of calcipotriol 50 lg/g (as hydrate) and
betamethasone 0.5 mg/g (as dipropionate) has been
developed to provide a highly effective topical
psoriasis treatment delivered in a more patient-
acceptable vehicle.
This aerosol foam formulation demonstrated a
significant improvement in clinical signs of psoriatic
lesions compared with the fixed combination
ointment, betamethasone aerosol foam and aerosol
foam vehicle alone.
The aerosol foam formulation may represent a more
efficacious alternative to current first-line topical
treatment options for patients with psoriasis vulgaris.
Clinical trial registration: NCT01347255.
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1 Introduction
Psoriasis vulgaris (plaque psoriasis) is a chronic, inflam-
matory disorder, typically with well-demarcated, erythe-
matous, thickened, scaly plaques on the body and scalp [1–
3]. The World Health Organization (WHO) recognizes that
psoriasis is a painful and debilitating disease [4] associated
with serious co-morbidities, such as cardiovascular disease,
diabetes mellitus and psoriatic arthritis [5, 6], as well as a
number of psychosocial disorders, including depression
[6]. As such, the negative impact of psoriasis on patients’
quality of life can be considerable [6, 7].
Topical therapy remains the mainstay of psoriasis treat-
ment, with more than 80 % of patients being able to manage
their psoriasis with topicals alone [8, 9]. Guidelines recom-
mend the topical use of corticosteroids and vitamin D ana-
logues (be it as monotherapies used in combination or as fixed
combinations) as first-line treatment for psoriasis [8, 9]. The
fixed combination of calcipotriol 50 lg/g (as hydrate; Cal)
and betamethasone 0.5 mg/g (as dipropionate; BD) has
demonstrated increased efficacy and reduced side effects
compared with either of the active ingredients when used as
monotherapies [10–12]. Furthermore, the presence of cal-
cipotriol may also provide an additive, steroid-sparing effect
on betamethasone dipropionate [3]. This combination is
currently available in gel or ointment formulations (Ta-
clonex/Daivobet/Dovobet), both of which are first-line
treatment options for patients with mild-to-moderate pso-
riasis vulgaris [8, 9].
An innovative aerosol foam formulation of the Cal/BD
fixed combination has now been developed to improve
topical treatment of psoriasis vulgaris. In this exploratory
study, the antipsoriatic effect of Cal/BD aerosol foam was
compared with that of the established fixed combination Cal/
BD ointment, as well as BD aerosol foam and Cal/BD aerosol
foam vehicle, using a modified version of the psoriatic plaque
test developed by Dumas and Scholtz [12–15].
2 Methods
2.1 Patients
Patients were at least 18 years of age, diagnosed with
psoriasis vulgaris of the body with psoriatic plaques of a
total size suitable for application of four different treat-
ments. Patients were required to have stable disease and
plaques with a total clinical score [TCS; sum of scores of
erythema, scaling and lesional thickness (each scored from
0 to 3)] of 4–9 inclusive and a score for each individual
component of C1. Disease stability was based on TCS
component scores measured at a screening visit (within
3 weeks of start of treatment) and baseline; disease was
considered stable if the change in score for any single
symptom was \1 point. Exclusion criteria included: treat-
ment with etanercept within 4 weeks, adalimumab, ale-
facept or infliximab within 2 months, or ustekinumab
within 4 months; any other biological or systemic therapy
within 4 weeks or five half-lives (whichever was longer);
psoralen combined with ultraviolet A or Grenz ray therapy
within 4 weeks or ultraviolet B therapy within 2 weeks;
potent or very potent (WHO class III–IV) corticosteroids
within 4 weeks; or emollients within 1 week. Topical an-
tipsoriatic treatment of the scalp and/or facial psoriasis
with WHO class I–II corticosteroids was allowed within
2 weeks of start of study treatment.
2.2 Study Design and Objectives
This was a single-centre, investigator-blinded, vehicle-
controlled, 4-week exploratory study (ClinicalTrials.gov
identifier: NCT01347255) with intra-individual compar-
ison, in which the following investigational products were
assessed: Cal/BD aerosol foam (LEO Pharma, Denmark),
Cal/BD ointment (Taclonex/Daivobet/Dovobet; LEO
Pharma, Denmark), BD aerosol foam and Cal/BD aerosol
foam vehicle. Each patient received simultaneous appli-
cation (by a study nurse/assistant) of all investigational
products to four predetermined target plaques on their
arms, legs or trunk, applied once daily (6 days per week,
excluding Sundays) for 4 weeks. Per patient, the test ap-
plication site for each product was determined according to
random assignment. Test sites (5 cm2) were delimited with
a disposable circular adhesive (replaced twice a week) and
outlined using an indelible marker. The minimum distance
allowed between two test sites was 2 cm. For application of
the aerosol foam products, 50 mg of product was sprayed
directly onto the appropriate test site, using a circular
template. Cal/BD ointment was applied using an Eppendorf
Combitip (Eppendorf AG, Hamburg, Germany). Each
product was gently massaged into the test sites with gloved
fingers and then non-occlusive gauze was applied until the
next treatment application.
The study was conducted in accordance with the ethical
principles of the Declaration of Helsinki and good clinical
practice guidelines. The study protocol was approved by
the independent ethics committee of the investigational
site. All patients provided written informed consent before
enrolment.
The primary objective was to evaluate the antipsoriatic
effect of Cal/BD aerosol foam compared with Cal/BD
ointment, BD aerosol foam and Cal/BD aerosol foam ve-
hicle, using the modified psoriasis plaque test. The sec-
ondary objective was to obtain information on adverse
events (AEs) for all investigational products.
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2.3 Assessments
Clinical and safety assessments were performed at baseline
and then twice weekly on days 4, 8, 11, 15, 18, 22, 25 and
29. Test site severity of erythema, scaling and lesional
thickness (using a 0–3 half-point grading scale) was
assessed by the investigator after removal of the non-oc-
clusive gauze and prior to treatment reapplication; a single
investigator performed all clinical assessments. Ultrasound
measurements were performed at baseline and once weekly
(days 8, 15, 22 and 29) using a B scanner equipped with a
20-MHz transducer. At each time point, three B scans were
made per test site. Safety and tolerability were assessed
throughout the study by evaluating AEs and adverse drug
reactions (ADRs).
2.4 Statistical Analysis
Twenty-four patients were required to achieve 80 % power
of rejecting the null hypothesis with a 5 % significance
level. The primary efficacy response was the change in
TCS (range 0–9) from baseline to week 4. Secondary ef-
ficacy responses included change from baseline in TCS and
its individual components (erythema, scaling and lesional
thickness), and ultrasound-determined total skin thickness
and echo-poor band thickness (a measure of superficial
dermis inflammation), by visit. Efficacy endpoints were
analysed by a two-way analysis of variance and are de-
scribed using summary statistics. All significance tests are
reported as two-sided with a 95 % confidence interval (CI).
All patients who received at least one dose of study treat-
ment were included in the full (intent-to-treat) and safety
analysis sets.
3 Results
3.1 Patient Disposition and Demographics
Between May and June 2011, 24 patients were enrolled in
this study, two-thirds of whom were male (Table 1). All
patients were exposed to all four investigational products,




At week 4, there was a significantly larger decrease in
mean [±standard deviation (SD)] TCS for those test
sites treated with Cal/BD aerosol foam (-6.00 ± 1.27)
compared with those treated with Cal/BD ointment
(-5.25 ± 1.78; difference -0.75; 95 % CI -1.46 to
-0.04; p = 0.038), BD aerosol foam (-4.96 ± 1.85; dif-
ference -1.04; 95 % CI -1.75 to -0.33; p = 0.005) or
Cal/BD aerosol foam vehicle (-1.88 ± 1.12; difference
-4.13; 95 % CI -4.83 to -3.42; p \ 0.001). A continuous
improvement in TCS was observed for all active treatments
throughout the study, with the mean decrease in TCS being
consistently larger with Cal/BD aerosol foam compared
with all other products, from the second on-treatment
assessment time point (day 8) until the end of the study
(Fig. 1a). Similarly, mean changes (±SD) in the TCS
components from baseline to week 4 were also found to be
higher for those test sites treated with Cal/BD aerosol foam
(erythema -1.75 ± 0.71; scaling -2.13 ± 0.47; lesional
thickness -2.13 ± 0.45) than for those treated with Cal/
BD ointment (-1.50 ± 0.66; -2.02 ± 0.56; -1.73 ±
0.82, respectively), BD aerosol foam (-1.44 ± 0.78;
-2.02 ± 0.58; -1.50 ± 0.77) and Cal/BD aerosol foam
vehicle (-0.56 ± 0.47; -0.90 ± 0.47; -0.42 ± 0.43;
Fig. 1b–d).
3.2.2 Ultrasound Assessment
Throughout this study, reductions in total skin thickness
and echo-poor band thickness were consistently greater
with Cal/BD aerosol foam treatment compared with all
other treatments. At week 4, treatment with Cal/BD aerosol
foam reduced the mean total skin thickness (±SD) to a
greater extent (-0.81 ± 0.41 mm), although not significantly
so, than with Cal/BD ointment (-0.62 ± 0.37 mm; differ-
ence, -0.19 mm; 95 % CI -0.40 to 0.03; p = 0.088) or BD
aerosol foam (-0.66 ± 0.42 mm; difference, -0.14 mm;
95 % CI -0.36 to 0.07; p = 0.190), and significantly greater
compared with Cal/BD aerosol foam vehicle (-0.23 ±
0.30 mm; difference, -0.58 mm; 95 % CI -0.79 to -0.36;
p\0.001; Fig. 2). Similarly, the mean reduction in echo-
poor band thickness at week 4 was consistently greater (but
Table 1 Patient demographics and baseline characteristics
Characteristic Value
Number of patients 24
Median (range) age, years 52.5 (21–75)
Males, n (%) 16 (66.7)
Fitzpatrick skin type,a n (%)
Type II 1 (4.2)
Type III 23 (95.8)
Median (range) disease duration, years 19.5 (3–49)
Mean ± standard deviation total clinical scoreb 7.07 ± 0.78
a Type II: white, always burns, tans minimally; Type III: white, burns
moderately, tans gradually (light brown)
b Sum of three scores (erythema, scaling, lesional thickness)
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again not significantly so) following treatment with Cal/BD
aerosol foam (-0.57 ± 0.21 mm) than with Cal/BD
ointment (-0.46 ± 0.21 mm; difference -0.11 mm; 95 %
CI -0.22 to 0.00; p = 0.052), and was significantly greater
compared with BD aerosol foam (-0.45 ± 0.25 mm; dif-
ference -0.12 mm; 95 % CI -0.23 to -0.01; p = 0.037)
and Cal/BD aerosol foam vehicle (-0.12 ± 0.20 mm; dif-
ference -0.44 mm; 95 % CI -0.55 to -0.33; p \0.001;
Fig. 3).
3.3 Safety and Tolerability
Seventeen AEs were reported by 11 patients during this
study, with the most common being headache (n = 5)
and arthralgia (n = 3) (Table 2). There were no reports
of serious AEs or ADRs and no withdrawals due to
AEs.
4 Discussion
This 4-week exploratory study demonstrated significant
improvement in antipsoriatic effect with the novel Cal/
BD aerosol foam formulation compared with the Cal/BD
ointment formulation, BD aerosol foam and Cal/BD
aerosol foam vehicle. The modified version of the pso-
riasis plaque test employed in this study is a quick, safe,
information-rich and relatively low-cost method to eval-
uate the antipsoriatic effect of psoriasis treatments. It
enables intra-individual comparisons and increases the
probability of detection of clinically relevant differences
despite the relatively short study period and limited
sample size [16].
The improved efficacy of other foam preparations over
conventional formulations of topical treatments in psoriasis
has been demonstrated in several studies. For example,
Cal/BD aerosol foam vehicle
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Cal/BD aerosol foam vehicle
Cal/BD aerosol foam Cal/BD ointment
BD aerosol foam
Fig. 1 Change from baseline (mean ± standard deviation) in a TCS, and its components b erythema, c scaling, and d lesional thickness, to end
of treatment. BD betamethasone 0.5 mg/g (as dipropionate), Cal calcipotriol 50 lg/g (as hydrate), TCS total clinical score
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clobetasol propionate in a foam formulation is more ef-
fective than the cream and solution formulations in de-
creasing Psoriasis Area and Severity Index score [17].
Similarly, betamethasone valerate is more effective in
improving psoriasis symptoms when delivered as foam
versus lotion [18, 19]. In addition to their application
advantage, foam vehicles have unique characteristics and
properties that can be engineered to enhance topical drug
delivery. Foam formulations of clobetasol propionate and
betamethasone valerate absorb more rapidly into the
skin, with greater total skin absorption than their re-
spective comparison formulations, namely, clobetasol
propionate solution and betamethasone valerate lotion
[20]. Furthermore, using an in vitro skin permeation
model, Huang et al. showed that foam vehicle delivers
more clobetasol propionate than other formulations (so-
lution, cream and lotion) and does so more efficiently
[21]. Consistent with these findings, an in vitro study
assessing skin penetration of the Cal/BD aerosol foam
demonstrated that the levels of diffusion of each active
ingredient into a skin model were consistently higher for
Cal/BD aerosol foam, with significantly higher steady-
state levels of Cal and BD, than Cal/BD ointment [22].
As well as providing a highly effective treatment, opti-
mizing drug delivery to the skin, the vehicle has also been
designed to provide a better user experience—to be a more
cosmetically acceptable preparation than current formula-
tions. Treatment non-adherence has been recognized as an
important and complex issue in disease management [23–
25]. For psoriasis treatment, the patient’s preference for
certain formulations and their perception of the efficacy of
their treatment are key factors affecting adherence [26–29].
Psoriasis patients are less willing to adhere to their topical
treatment if they find application to be cumbersome and
time consuming [26, 27, 30], and comparisons of treatment
vehicles have shown that patients prefer more cosmetically
elegant formulations, such as foam vehicles, which are
convenient and easy to use, thereby minimizing impact on

































Cal/BD aerosol foam vehicle
Cal/BD aerosol foam Cal/BD ointment
BD aerosol foam
Fig. 2 Change from baseline (mean ± standard deviation) in total
skin thickness (assessed by ultrasonographic imagery) to end of
treatment. BD betamethasone 0.5 mg/g (as dipropionate), Cal



































Cal/BD aerosol foam vehicle
Cal/BD aerosol foam Cal/BD ointment
BD aerosol foam
Fig. 3 Change from baseline (mean ± standard deviation) in echo-
poor band thickness (assessed by ultrasonography) to end of
treatment. BD betamethasone 0.5 mg/g (as dipropionate), Cal
calcipotriol 50 lg/g (as hydrate)
Table 2 Adverse events according to the Medical Dictionary for
Regulatory Activities (MedDRA) primary system organ class and
preferred term
Adverse event Patients, n (%)a
Nervous system disorders 6 (25.0)
Headache 5 (20.8)
Sciatica 1 (4.2)
Musculoskeletal and connective tissue disorders 4 (16.7)
Arthralgia 3 (12.5)
Back pain 1 (4.2)
Gastrointestinal disorders 3 (12.5)
Diarrhoea 1 (4.2)
Toothache 2 (8.3)
Infections and infestations 2 (8.3)
Gastroenteritis 1 (4.2)
Nasopharyngitis 1 (4.2)
Eye disorders 1 (4.2)
Conjunctivitis 1 (4.2)




Classification according to MedDRA version 6.1
a Patients may have had more than one adverse event
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5 Conclusion
In conclusion, this exploratory study has demonstrated a
superior antipsoriatic effect with Cal/BD aerosol foam
compared with Cal/BD ointment, BD aerosol foam and
Cal/BD aerosol foam vehicle. The aerosol foam formula-
tion may represent a more efficacious and acceptable al-
ternative to well-established, conventional formulations of
Cal/BD.
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